Microsoft word - faq_mutations.doc

Antiviral resistance
(SUBTYPE) isolates
Ose. Zan.
Table 1: List of mutations used to compute antiviral resistance and putative human
adaptation. Ose.: Oseltamivir. Zan.: Zanamivir. Per.: Peramivir. Adam.: Adamantanes.
Hum. adapt.: Human adaptation. Ref.; bibliographic reference number. High
pathogenicity: could contribute, alone or in association with other mutations, to a higher
pathogenicity in avians and/or mammals. +++: high level of confidence; ++: medium
level of confidence; +: low level of confidence, or in correlation with other
mutations; (M): mammals only.
Hay A.J., Zambon M.C., Wolstenholme A.J., Skehel J.J. and Smith M.H. (1986)
Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob
18 Suppl B,19-29.
Belshe R.B., Smith M.H., Hal C.B., Betts R. and Hay A.J. (1988) Genetic basis of
resistance to rimantadine emerging during treatment of influenza virus infection. J
62(5), 1508-1512.
Cox N.J., Kawaoka Y. (1998), Orthomyxoviruses: influenza. In: Col ier L., Balows
A., Sussman M., eds. Topley & Wilson's Microbiology and Microbial Infections, Vol
1. Virology. London: Arnold, 385-433.
Gabriel G., Abram M., Keiner B., Wagner R., et al. (2007) Differential polymerase
activity in avian and mammalian cel s determines host range of influenza virus. J
81(17), 9601-9604.
Basler C.F. and Aguilar P.V. (2008) Progress in identifying virulence determinants
of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses. Antiviral Res
79(3), 166-178.
Ferraris O. and Lina B. (2008) Mutations of neuraminidase implicated in
neuraminidase inhibitors resistance. Journal of Clinical Virology, 41, 13-19.
Korteweg C. and Gu J. (2008) Pathology, molecular biology, and pathogenesis of
avian influenza A (H5N1) infection in humans. Am J Pathol 172(5),1155-1170.
Hulse D.J., Webster R.G., Russel R.J. and Perez D.R. (2004) Molecular
determinants within the surface proteins involved in the pathogenicity of H5N1
influenza viruses in chickens. J Virol 78(18) 9954-9964.
Steinhauer D.A. (1999) Role of hemagglutinin cleavage for the pathogenicity of
influenza virus. Virology 258(1) 1-20.
Seo S.H., Hoffmann E., Webster R.G. (2002) Lethal H5N1 influenza viruses escape
host anti-viral cytokine responses. Nat Med 8(9) 950-954.
Long J.X., Peng D.X., Liu Y.L., Wu Y.T. and Liu X.F. (2008). Virulence of H5N1
avian influenza virus enhanced by a 15-nucleotide deletion in the viral nonstructural
gene. Virus Genes 36(3) 471-478.
Conenel o G.M., Zamarin D., Perrone L.A., Tumpey T. and Palese P. (2007) A
single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses
contributes to increased virulence. PLoS Pathog 3(10) 1414-1421.
Le Q.M., Sakai-Tagawa Y., Ozawa M., Ito M., Kawaoka Y. (2009) Selection of
H5N1 influenza virus PB2 during replication in humans. J Virol 83(10) 5278-5281.
Li Z., Chen H., Jiao P., Deng G. et al. (2005) Molecular basis of replication of duck
H5N1 influenza viruses in a mammalian mouse model. J Virol 79(18) 12058-12064.
Gabriel G., Dauber B. Wolff T., Planz O. et al. (2005) The viral polymerase
mediates adaptation of an avian influenza virus to a mammalian host. Proc Natl
Acad Sci USA
102(51) 18590-18595.
ViralZone (2009). Abed Y., Nehmé B., Baz M., Boivin G. (2008) Activity of the neuraminidase inhibitor
A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2
subtypes. Antiviral Res. 77(2),163-166.
Gubareva L.V., Kaiser L., Matrosovich M.N., Soo-Hoo Y., Hayden F.G. (2001)
Selection of influenza virus mutants in experimental y infected volunteers treated
with oseltamivir. J. Infect. Dis. 183, 523–531.
Gubareva L.V., Webster R.G., Hayden F.G. (2001) Comparison of the activities of
zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus
and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 45,
Gubareva L.V., Nedyalkova M.S., Novikov D.V., Murti K.G., Hoffmann E., Hayden
F.G. (2002) A release-competent influenza A virus mutant lacking the coding
capacity for the neuraminidase active site. J. Gen. Virol. 8, 2683–2692.
Gubareva L.V., Webster R.G., Hayden F.G. (2002) Detection of influenza virus
resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res.
53, 47–61.
Gubareva L.V. (2004) Molecular mechanisms of influenza virus resistance to
neuraminidase inhibitors. Virus Res. 103(1-2), 199-203.
Carr J., Ives J., Kel y, L., et al. (2002) Influenza virus carrying neuraminidase with
reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is
compromised for infectivity and replicative ability in vivo. Antiviral Res. 54, 79–88.
Ives J., Carr J., Roberts N.A., Tai C.Y., Mendel D.B., Kel y L., Lambkin R., Oxford
J.(2000) An oseltamivir treatment selected influenza A/Wuhan/359/95 virus with a
E119V mutation in the neuraminidase gene has reduced infectivity in vivo. J. Clin.
. 18, 251–269.
Ives J.A., Carr J.A., Mendel D.B., et al. (2002) The H274Y mutation in the influenza
A/H1N1 neuraminidase active site folowing oseltamivir phosphate treatment leave
virus severely compromised both in vitro and in vivo. Antiviral Res. 55, 307–317.
Jackson D., Barclay W., Zürcher T. (2005) Characterization of recombinant
influenza B viruses with key neuraminidase inhibitor resistance mutations. J
Antimicrob Chemother
. 55(2), 162-169.
Mishin V.P., Hayden F.G., Gubareva L.V. (2005) Susceptibilities of antiviral-
resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents
. 49(11), 4515-4520.
Monto A.S., McKimm-Breschkin J.L., Macken C., Hampson A.W., Hay A., Klimov
A., Tashiro M., Webster R.G., Aymard M., Hayden F.G., Zambon M. (2006)
Detection of influenza viruses resistant to neuraminidase inhibitors in global
surveil ance during the first 3 years of their use. Antimicrob Agents Chemother.
50(7), 2395-2402.
Ilyushina N.A., Govorkova E.A., Webster R.G. (2005) Detection of amantadine-
resistant variants among avian influenza viruses isolated in North America and
Asia. Virology. 341(1), 102-106.
Abed Y., Goyette N., Boivin G. (2005) Generation and characterization of
recombinant influenza A (H1N1) viruses harboring amantadine resistance
mutations. Antimicrob Agents Chemother. 49(2), 556-559.



If you are taking Aspirin (or like products, see last page) you should stop it 7 days prior to this procedure. Please talk to your Physician. or two. This is due to the mechanical process of HOW LONG DOES THE INJECTION needle insertion as well as initial irritation from the steroid itself. The cortisone starts working in The actual injection takes only a few minutes, but about 1 to

Lithium ion cgr17500

LITHIUM ION BATTERIES: INDIVIDUAL DATA SHEET CGR17500 CGR17500: Cylindrical Model Discharge Characteristics Charge Conditions: Constant voltage/constant current, 4.2 V, 550 mA (max.), 2 hours, 20˚C. Discharge Conditions: Constant current up to 3.0V at 20˚C. Charge Conditions: Constant voltage/constant current, 4.2 V, 550 mA (max.), 2 hours, 20˚C. Discharge Conditions: Con

© 2010-2014 Pdf Medical Search